Description

Ibutamoren (MK-677) ZPHC — 20 mg (100 tablets × 20 mg) | Research-Grade Growth Hormone Secretagogue

Product Code: MK-677-ZPHC-20MG
Price: $129.00

---

Product Overview

Ibutamoren (MK-677) is a potent, orally active growth hormone secretagogue receptor (GHSR) agonist that mimics the action of the endogenous hormone ghrelin . This non-peptide compound stimulates the pituitary gland to enhance pulsatile growth hormone release, leading to sustained elevations in both growth hormone and insulin-like growth factor 1 (IGF-1) levels .

The ZPHC pharmaceutical-grade presentation offers 100 film-coated, scored tablets each containing 20 mg of high-purity Ibutamoren, providing researchers with a precisely dosed, reliable research material for controlled investigations into the GH-IGF-1 axis.

---

Key Research Applications

Growth Hormone and IGF-1 Axis Modulation

Ibutamoren acts as a potent agonist at the growth hormone secretagogue receptor, demonstrating an EC50 value of 1.3 nM for stimulating growth hormone release from pituitary cells . Clinical research has shown that oral administration produces dose-dependent increases in GH concentrations, with 25 mg daily enhancing mean 24-hour GH concentration by approximately 97% in healthy elderly subjects . Serum IGF-I levels increase approximately 40-52% with sustained administration, restoring levels to those typically observed in young adults .

Body Composition Research

Controlled studies demonstrate that Ibutamoren administration promotes anabolic changes in body composition. An 8-week randomized, double-blind, placebo-controlled trial in obese males showed significant increases in fat-free mass when measured via dual-energy X-ray absorptiometry, with sustained elevation of GH, IGF-I, and IGF-binding protein-3 . The compound also transiently increases basal metabolic rate, with significant effects observed at 2 weeks of treatment .

Bone Metabolism Investigation

Research indicates that Ibutamoren stimulates markers of bone turnover in elderly populations. Dose-response studies demonstrate that 10 mg and 25 mg doses increase urinary N-telopeptide cross-links by 10% and 17% respectively, while serum osteocalcin increases by 8-29% over treatment periods of 2-9 weeks . These findings suggest potential applications in bone metabolism research.

Sustained 24-Hour Action

The compound demonstrates a long half-life enabling once-daily oral administration with sustained IGF-1 elevation for approximately 24 hours following a single dose . Research protocols typically employ daily administration before bedtime to align with natural growth hormone pulsatility patterns.

---

Product Specifications

---

Quality Assurance

ZPHC batches undergo comprehensive quality control testing including:

• HPLC purity verification (>99%)

• Heavy metal screening

• Microbiological clearance

• Authenticity scratch-code verification system

• Tamper-evident packaging with sealed blisters

---

Research Use Information

Typical Research Protocols

• Dosage Range: 10-30 mg daily, administered orally

• Study Duration: 8-16 weeks typical for body composition and metabolic studies 

• Administration: Once daily, often before bedtime to align with natural GH pulsatility

• Combination Research: Frequently studied in conjunction with HGH, peptides, or SARMs for synergistic pathway investigation

Storage Recommendations

• Store at room temperature in sealed container

• Protect from moisture and oxidation

• Refer to manufacturer’s expiration dating on packaging

---

Safety and Handling Information

Important Research Considerations:

Research subjects should be monitored for:

• Fasting blood glucose and insulin sensitivity 

• Blood pressure changes

• Appetite stimulation (ghrelin-receptor mediated)

• Mild lower-extremity edema 

• Transient increases in prolactin (remain within normal range) 

Contraindications for Research Subjects:

• Active cancer

• Uncontrolled diabetes or significant insulin resistance

• History of heart failure

• Pregnancy or breastfeeding

This product is for laboratory and research use only. Not for human therapeutic, diagnostic, or veterinary use.

---

Frequently Asked Questions

1. What is Ibutamoren (MK-677) and how does it work?
Ibutamoren is an orally active, non-peptide growth hormone secretagogue that acts as a ghrelin receptor agonist . It stimulates the pituitary gland to release growth hormone in a pulsatile pattern, leading to sustained increases in both GH and IGF-1 levels. Unlike exogenous growth hormone administration, it works by enhancing the body’s natural production mechanisms .

2. What is the recommended dosage for research purposes?
Clinical studies have employed doses ranging from 10-25 mg daily . The scored 20 mg tablets allow for flexible dosing, including 10 mg (half tablet) for lower-dose protocols. Most research protocols utilize once-daily administration, typically before bedtime.

3. What are the documented effects on growth hormone and IGF-1 levels?
Research demonstrates that 25 mg daily increases mean 24-hour GH concentration by approximately 97% in elderly subjects . Serum IGF-I increases approximately 40-52% with sustained treatment . These elevations are sustained throughout the treatment period.

4. What body composition changes have been observed in research?
Controlled studies show significant increases in fat-free mass when measured by dual-energy X-ray absorptiometry . The compound also produces a transient increase in basal metabolic rate at 2 weeks of treatment . Some studies note improvement in lean body mass and recovery markers .

5. Are there effects on bone metabolism?
Yes, research indicates that Ibutamoren stimulates bone turnover markers. Studies demonstrate increases in urinary N-telopeptide cross-links (bone resorption marker) by 17-22% and serum osteocalcin (bone formation marker) by 8-29% over various treatment periods .

6. What is the purity and quality control standard for this product?
ZPHC batches undergo comprehensive testing including HPLC purity verification (>99%), heavy metal screening, and microbiological clearance. Each box features a scratch-code authenticity verification system and tamper-evident packaging with sealed blisters.

7. What are the observed effects on glucose metabolism?
Research shows that Ibutamoren can increase fasting glucose and may impair glucose tolerance during oral glucose tolerance testing . Subjects with pre-existing diabetes or insulin resistance should be carefully monitored. Fasting glucose increases of approximately 0.3 mmol/L have been documented in clinical trials .

8. How should this product be stored?
Store in a sealed container at room temperature, protected from moisture and oxidation . Refer to the manufacturer’s expiration dating on the packaging for specific storage requirements.

9. What is the duration of typical research protocols?
Clinical studies have employed treatment periods ranging from 2-16 weeks . The 8-week protocol is well-documented in body composition research . Longer-term studies up to 12 months have also been conducted .

10. Is Ibutamoren FDA-approved?
Ibutamoren is not FDA-approved for any clinical use. The FDA’s Pharmacy Compounding Advisory Committee voted against including ibutamoren on the 503A bulks list in October 2024, citing insufficient safety data and concerns about hyperglycemia and potential cardiac risks . This product is for laboratory and research use only.

---

Reputable Research References

1. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369. [PubMed: 9467542] 

2. Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. 

3. Murphy MG, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Clin Endocrinol Metab. 1999;84(8):2799-2806. 

4. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. [cited in citation:7]

5. MedChemExpress. Ibutamoren (MK-677) Product Data Sheet. HY-10199A. 

6. TargetMol. Ibutamoren (MK-677) Product Information. T20095. 

---

Related Products and Research Materials

• HGH (Human Growth Hormone) Research Products

• Peptide Research Materials (CJC-1295, Ipamorelin, GHRP-2, GHRP-6)

• SARMs Research Products

• Complete Research Protocols and Cycle Guides

---

Shipping and Handling: All orders are shipped worldwide with tracked delivery. Secure, discreet packaging ensures product integrity during transit.

Authenticity Verification: Each box contains a scratch-code authentication system for product verification.